Literature DB >> 29272057

Clinical usefulness of prognostic biomarkers in optic neuritis.

A Tejeda-Velarde1,2, L Costa-Frossard2,3, S Sainz de la Maza2,3, Á Carrasco1, M Espiño1,2, C Picón1,2, I Toboso1,2, P E Walo1, D Lourido4, A Muriel5, J C Álvarez-Cermeño2,3,6, L M Villar1,2.   

Abstract

BACKGROUND AND
PURPOSE: Different biological and radiological biomarkers predict clinical conversion to multiple sclerosis (MS) after a clinically isolated syndrome (CIS). The aim was to explore their role in predicting the outcome of patients with optic neuritis (ON), a CIS considered to have a benign prognosis.
METHODS: Sixty-eight consecutive ON patients were followed prospectively. Magnetic resonance imaging (MRI) and cerebrospinal fluid studies including oligoclonal immunoglobulin G (IgG) bands (OCGBs), lipid-specific oligoclonal IgM bands (LS-OCMBs) and neurofilament light chain quantification were performed at disease onset. Conversion to clinically definite MS (CDMS) was monitored.
RESULTS: The mean time of follow-up of our series was 46.4 months. Twenty-five patients (36.7%) developed CDMS during follow-up. Neurofilament light chain levels did not predict clinical conversion. By contrast, an abnormal MRI increased the risk of CDMS [hazard ratio (HR) 12.5, P = 0.013]. The clearest association was found in patients with more than three T2 lesions. OCGBs also predicted the onset of CDMS (HR 21.3, P = 0.003) and LS-OCMBs were associated with a shorter time to CDMS (HR = 116.6, P < 0.001).
CONCLUSIONS: Magnetic resonance imaging and OCGBs predicted conversion to CDMS after an ON episode. In addition, LS-OCMBs identified the ON patients more likely to develop MS early. These results, applicable to the everyday clinical setting, may be of interest for therapeutic decisions.
© 2017 EAN.

Entities:  

Keywords:  antibodies; demyelinating diseases; multiple sclerosis; optic neuritis

Mesh:

Substances:

Year:  2018        PMID: 29272057     DOI: 10.1111/ene.13553

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  7 in total

1.  Molecular Biomarkers for Glaucoma.

Authors:  Gala Beykin; Jeffrey L Goldberg
Journal:  Curr Ophthalmol Rep       Date:  2019-07-23

Review 2.  Atypical optic neuritis: An overview.

Authors:  Prathama Sarkar; Amit Mehtani; H C Gandhi; Vinita Dubey; Parag Maroti Tembhurde; Mohit Kumar Gupta
Journal:  Indian J Ophthalmol       Date:  2021-01       Impact factor: 1.848

3.  Serum neurofilament levels reflect outer retinal layer changes in multiple sclerosis.

Authors:  Caspar B Seitz; Falk Steffen; Muthuraman Muthuraman; Timo Uphaus; Julia Krämer; Sven G Meuth; Philipp Albrecht; Sergiu Groppa; Frauke Zipp; Stefan Bittner; Vinzenz Fleischer
Journal:  Ther Adv Neurol Disord       Date:  2021-05-25       Impact factor: 6.570

4.  Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis.

Authors:  Igal Rosenstein; Sofia Rasch; Markus Axelsson; Lenka Novakova; Kaj Blennow; Henrik Zetterberg; Jan Lycke
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

Review 5.  Discovery and clinical translation of novel glaucoma biomarkers.

Authors:  Gala Beykin; Anthony M Norcia; Vivek J Srinivasan; Alfredo Dubra; Jeffrey L Goldberg
Journal:  Prog Retin Eye Res       Date:  2020-07-10       Impact factor: 21.198

6.  Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome.

Authors:  Enric Monreal; Susana Sainz de la Maza; Lucienne Costa-Frossard; Paulette Walo-Delgado; Javier Zamora; José Ignacio Fernández-Velasco; Noelia Villarrubia; Mercedes Espiño; Daniel Lourido; Paloma Lapuente; Inmaculada Toboso; José Carlos Álvarez-Cermeño; Jaime Masjuan; Luisa María Villar
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-07-22

Review 7.  Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in.

Authors:  Jeroen Van Schependom; Kaat Guldolf; Marie Béatrice D'hooghe; Guy Nagels; Miguel D'haeseleer
Journal:  Transl Neurodegener       Date:  2019-12-09       Impact factor: 8.014

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.